GlobeNewsWire
15 Jun 2026, 17:36 UTC · 13w ago
Verdict
Headline takes no side. We score NORD +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Orocidin's QR-01 candidate demonstrated efficacy in two animal studies and is expected to begin Phase IIa human clinical trials in the first half of 2027.
More positive than 92% of claims this week
Nordicus Partners is currently in the process of applying to uplist its common shares from the OTCQB to a major stock exchange.
So whatUplisting typically increases liquidity and institutional visibility, which generally supports a higher valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
Bio-Convert's QR-02 candidate received a toxicity waiver from the Danish Medicine Agency and is expected to enter Phase IIa trials in early 2027.
More positive than 65% of claims this week
NoviThera's QR-04 treatment for psoriasis has demonstrated biological proof of concept in a recent mouse study.
More positive than 55% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported successful animal studies for QR-01, a toxicity waiver for QR-02, and biological proof of concept for QR-04, alongside an ongoing Nasdaq uplisting process.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
51m ago
−12.0%
Price is moving against the score
$3.30 vs $3.75 close before publication (Jun 12) · not market-adjusted
NORD chart →
